Advertisement

Role of HIPEC in the Prevention of Peritoneal Metastasis from Colorectal, Gastric and Appendiceal Cancer

  • Ramakrishnan Ayloor Seshadri
  • Akash Meinte Mehta
Chapter

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have offered new hope for patients with peritoneal metastasis from colorectal and gastric cancers. However, this treatment can be offered only to a small, select group of patients, and even in this select group, only a small proportion can be cured. Hence, prevention of peritoneal metastasis assumes importance. Currently, three approaches are being evaluated to prevent colorectal peritoneal metastasis using HIPEC: a proactive approach, in patients considered to be at high risk of microscopic peritoneal dissemination; an adjuvant approach, in the immediate or delayed postoperative period after primary resection; and a second-look approach, during a systematic second-look operation approximately 1 year after primary resection. The effectiveness of HIPEC in preventing gastric peritoneal metastasis has already been shown in a number of randomised studies from Asia and is also currently being evaluated in Western patients. The results of ongoing trials could well be a game changer in the prevention of colorectal and gastric cancer-associated peritoneal metastasis. Unlike colorectal and gastric cancer, mucinous appendiceal neoplasms, which are the commonest cause of pseudomyxoma peritonei, pursue a more indolent course, and even patients with extensive disease are amenable to curative resection. However, early diagnosis can lead to a prolongation in survival, and strategies to prevent peritoneal dissemination are recommended during surgery for mucinous appendiceal neoplasms.

Keywords

Colorectal cancer Gastric cancer Peritoneal metastasis Mucinous appendiceal neoplasms Hyperthermic intraperitoneal chemotherapy Cytoreductive surgery Prevention Prophylactic Proactive Second-look surgery Adjuvant HIPEC 

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. Accessed on 01.03.2015. Available from: URL: http://globocan.iarc.fr.Google Scholar
  2. 2.
    Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25.CrossRefPubMedGoogle Scholar
  3. 3.
    van Gestel YR, Thomassen I, Lemmens VE, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40:963–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Sakuramoto S, Sasako M, Yamaguchi T, For the ACTS-GC group, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Roviello F, Marrelli D, de Manzoni G, on behalf of the Italian Research Group for Gastric Cancer, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Cunningham D, Allum WH, Stenning SP, MAGIC Trial Participants, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Bang YJ, Kim YW, Yang HK, CLASSIC Trial Investigators, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116:a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Xiong B, Ma L, Cheng Y, et al. Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials. Eur J Surg Oncol. 2014;40:1321–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Cao J, Qi F, Liu T. Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis. Scand J Gastroenterol. 2014;49:690–704.CrossRefPubMedGoogle Scholar
  12. 12.
    Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Shirao K, Boku N, Yamada Y, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, et al. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106) for the gastrointestinal oncology study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 2013;43:972–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Hong SH, Shin YR, Roh SY, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013;16:290–300.CrossRefPubMedGoogle Scholar
  17. 17.
    Tamura S, Miki H, Okada K, et al. Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer. Gastric Cancer. 2010;13:101–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016;22(3):1114–30.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chia CS, Seshadri RA, Kepenekian V, et al. Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. Pleura Peritoneum. 2016;1:67–77.CrossRefGoogle Scholar
  25. 25.
    Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46.CrossRefPubMedGoogle Scholar
  28. 28.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Leung V, Huo YR, Liauw W, et al. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2016;43(1):144–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Moran B, Cecil T, Chandrakumaran K, et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Color Dis. 2015;17:772–8.CrossRefGoogle Scholar
  31. 31.
    Sugarbaker PH, Schellinx ME, Chang D, et al. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996;20:585–91. discussion 592.CrossRefPubMedGoogle Scholar
  32. 32.
    Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.CrossRefPubMedGoogle Scholar
  33. 33.
    Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer. 1997;79:884–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85–97.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Fujimura T, Yonemura Y, Fushida S, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer. 1990;65:65–71.CrossRefPubMedGoogle Scholar
  36. 36.
    Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005;92:370–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Glehen O, Gilly FN, Arvieux C, Association Française de Chirurgie, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Yang X-J, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010;101:457–64.CrossRefPubMedGoogle Scholar
  39. 39.
    Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:911–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Koh JL, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.CrossRefPubMedGoogle Scholar
  42. 42.
    Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36:1131–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–48.CrossRefPubMedGoogle Scholar
  44. 44.
    Juhl H, Stritzel M, Wroblewski A, et al. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer. 1994;57:330–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Han TS, Kong SH, Lee HJ, et al. Dissemination of free cancer cells from the gastric lumen and from perigastric lymphovascular pedicles during radical gastric cancer surgery. Ann Surg Oncol. 2011;18:2818–25.CrossRefPubMedGoogle Scholar
  46. 46.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(Suppl 6):83–97.PubMedGoogle Scholar
  47. 47.
    Moran BJ, Cecil TD. Treatment of surgically resectable colorectal peritoneal metastases. Br J Surg. 2014;101:5–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Elias D, Honore C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–93.CrossRefPubMedGoogle Scholar
  49. 49.
    Honore C, Goere D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.CrossRefPubMedGoogle Scholar
  50. 50.
    Delhorme JB, Triki E, Romain B, et al. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis. J Visc Surg. 2015;152:149–54.CrossRefPubMedGoogle Scholar
  51. 51.
    Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol. 2012;23:3123–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Klaver CE, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Zanghi A, Cavallaro A, Piccolo G, et al. Dissemination metastasis after laparoscopic colorectal surgery versus conventional open surgery for colorectal cancer: a metanalysis. Eur Rev Med Pharmacol Sci. 2013;17:1174–84.PubMedGoogle Scholar
  54. 54.
    Kerscher AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108:1432–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Sammartino P, Sibio S, Biacchi D, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Sugarbaker PH, Gianola FJ, Speyer JC, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414–22.PubMedGoogle Scholar
  57. 57.
    Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer. 1998;77:1349–54.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Vaillant JC, Nordlinger B, Deuffic S, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231:449–56.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol. 2002;79:46–61.CrossRefPubMedGoogle Scholar
  60. 60.
    Noura S, Ohue M, Shingai T, et al. Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol. 2011;18:396–404.CrossRefPubMedGoogle Scholar
  61. 61.
    Tentes AA, Spiliotis ID, Korakianitis OS, et al. Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: preliminary results. ISRN Surg. 2011;2011:529876.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Sammartino P, Sibio S, Biacchi D, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Color Dis. 2014;29:1081–9.CrossRefGoogle Scholar
  63. 63.
    Sloothaak DA, Mirck B, Punt CJ, et al. Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review. Br J Cancer. 2014;111:1112–21.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Sammartino P, Biacchi D, Cornali T, et al. Proactive management for gastric, colorectal and appendiceal malignancies: preventing peritoneal metastases with hyperthermic intraperitoneal chemotherapy (HIPEC). Indian J Surg Oncol. 2016;7:215–24.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Aoyama T, Yoshikawa T, Hayashi T, et al. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol. 2012;19:1568–74.CrossRefPubMedGoogle Scholar
  66. 66.
    Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178:256–62.CrossRefPubMedGoogle Scholar
  67. 67.
    Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12:347–53.CrossRefPubMedGoogle Scholar
  68. 68.
    Kodera Y, Yamamura Y, Shimizu Y, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol. 1999;72:60–4.CrossRefPubMedGoogle Scholar
  69. 69.
    Koga S, Hamazoe R, Maeta M, et al. Prophylactic cancer therapy for peritoneal recurrence of gastric by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988;61:232–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer – final results of a randomised controlled study. Cancer. 1994;73:2048–52.CrossRefPubMedGoogle Scholar
  71. 71.
    Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 1994;18:150–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Ikeguchi M, Kondou A, Oka A, et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg. 1995;161:581–6.PubMedGoogle Scholar
  73. 73.
    Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85:529–34.CrossRefPubMedGoogle Scholar
  74. 74.
    Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology. 1999;57:106–14.CrossRefPubMedGoogle Scholar
  75. 75.
    Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterology. 2001;48:1776–82.PubMedGoogle Scholar
  76. 76.
    Kim JY, Bae HS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer. 2001;4:27–33.CrossRefPubMedGoogle Scholar
  77. 77.
    Yonemura Y, Shinbo M, Hagiwara A, et al. Treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Gastroenterological Surgery. 2008;31:802–12.Google Scholar
  78. 78.
    Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21:1147–52.CrossRefPubMedGoogle Scholar
  79. 79.
    Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg. 1995;19:565–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25:985–90.CrossRefPubMedGoogle Scholar
  81. 81.
    Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Mi DH, Li Z, Yang K-H, et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperth. 2013;29:156–67.CrossRefGoogle Scholar
  83. 83.
    Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicentre phase III study. BMC Cancer. 2014;14:183.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Roviello F, Caruso S, Neri A, et al. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39:1309–16.CrossRefPubMedGoogle Scholar
  85. 85.
    Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–6.CrossRefPubMedGoogle Scholar
  86. 86.
    Sugarbaker PH. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: Sugarbaker PH, editor. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. Woodbury: Cine-Med Publishers; 2012.Google Scholar
  87. 87.
    Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol. 2004;21:134–50.CrossRefPubMedGoogle Scholar
  88. 88.
    Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems and proposed classification. Adv Anat Pathol. 2005;12:291–311.CrossRefPubMedGoogle Scholar
  89. 89.
    Ansari N, Chandrakumaran K, Dayal S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035–41.CrossRefPubMedGoogle Scholar
  90. 90.
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMedGoogle Scholar
  91. 91.
    Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196–201.CrossRefPubMedGoogle Scholar
  92. 92.
    Murphy EM, Farquharson SM, Moran BJ. Management of an unexpected appendiceal neoplasm. Br J Surg. 2006;93:783–92.CrossRefPubMedGoogle Scholar
  93. 93.
    Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089–103.CrossRefPubMedGoogle Scholar
  94. 94.
    McDonald JR, O’Dwyer ST, Rout S, et al. Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg. 2012;99(7):987–92.CrossRefPubMedGoogle Scholar
  95. 95.
    Honoré C, Caruso F, Dartigues P, et al. Strategies for preventing pseudomyxoma peritonei after resection of a mucinous neoplasm of the appendix. Anticancer Res. 2015;35(9):4943–7.PubMedGoogle Scholar
  96. 96.
    Foster JM, Sleightholm RL, Wahlmeier S, et al. Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis. World J Surg Oncol. 2016;14(1):243.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Dhage-Ivatury S, Sugarbaker PH. Update on the surgical approach to mucocele of the appendix. J Am Coll Surg. 2006;202:680–4.CrossRefPubMedGoogle Scholar
  98. 98.
    Chiu CC, Wei PL, Huang MT, et al. Laparoscopic resection of appendiceal mucinous cystadenoma. J Laparoendosc Adv Surg Tech A. 2005;15:325–8.CrossRefPubMedGoogle Scholar
  99. 99.
    Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer J. 2009;15:225–35.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Ramakrishnan Ayloor Seshadri
    • 1
  • Akash Meinte Mehta
    • 2
  1. 1.Department of Surgical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Peritoneal Malignancy Institute, North Hampshire Hospital, Hampshire Hospitals NHS Foundation TrustBasingstokeUK

Personalised recommendations